← Story archive
Markets
Revolution Medicines stock price target kept at $270 by TD Cowen on cancer data
Follow the evidence
Read the original report, then compare company disclosures and the relevant official data. A headline alone does not establish an effect on markets.
No additional matched coverage has been archived for this story yet.
This page preserves an attributed headline and brief excerpt. The publisher maintains the original report and any subsequent corrections. Report a classification or link issue →